Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
LENSAR, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/11/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
08/04/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
08/04/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/14/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
06/08/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/19/2023 SC 13D NORTH RUN CAPITAL, LP reports a 20% stake in LENSAR, Inc.
05/18/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock filed May 18, 2023",
"Class A Common Stock Purchase Warrant",
"Class B Common Stock Purchase Warrant",
"Form of Voting Agreement between NR-GRI Partners, LP, and each of the executive officers and directors of LENSAR, Inc"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Form of Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock",
"Form of Common Stock Purchase Warrant",
"Securities Purchase Agreement, between LENSAR, Inc. and NR-GRI Partners, LP",
"Registration Rights Agreement, between LENSAR, Inc. and NR-GRI Partners, LP"
05/15/2023 8-K Quarterly results
Docs: "LENSAR Reports First Quarter 2023 Results and Provides Business Update Increased ALLY® Adaptive Cataract Treatment System installed base to 19 systems with a backlog of additional 13 systems as of May 12, 2023 U.S. procedure volumes increased 13% over first quarter 2022; Procedure volumes increased >20% year-over-year at sites that have upgraded from LENSAR Laser System to ALLY Significantly strengthened balance sheet through $20 million private placement ORLANDO, Fla. – LENSAR, Inc. , a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2023 and provided an update on key operational initiatives. “I am thrilled with the growing momentum ALLY is ex..."
04/20/2023 ARS Form ARS - Annual Report to Security Holders:
03/20/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Quarterly results
Docs: "LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Installed ten ALLY® Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 2022; Installations expected in first half 2023 Positive surgeon feedback reinforces next generation speed, efficiency and economic benefits of ALLY ORLANDO, Fla. – LENSAR, Inc. , a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2022 and provided an update on key operational initiatives. “The reception to our next generation ALLY System supports our confidence in this new technology and its potential to change th..."
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 8-K Quarterly results
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2023 SC 13G/A CURTIS NICHOLAS T reports a 7.4% stake in LENSAR, Inc.
01/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
Docs: "LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update Company Launches ALLY™ Adaptive Cataract Treatment System Third Quarter U.S. Procedure Volume Increases 9% over Q3 2021 ORLANDO, Fla. – LENSAR, Inc. , a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2022 and provided a business update. “The third quarter was highlighted by the successful U.S. launch of the ALLY System during the week of August 15th, a pivotal corporate milestone, and the next important step in continuing the transition to our next generation system. We have installed multiple ALLY Systems in select sites with surgeons performing cases with th..."
09/08/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EU ORLANDO, Fla. – LENSAR, Inc. , a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for certification of the ALLY™ Adaptive Cataract Treatment System in the European Union. “Following the FDA clearance of ALLY in June 2022 and recent U.S. commercial launch, this is another important step in our effort to bring ALLY to cataract surgeons in key global markets. Our mission has always been to create a platform that optimizes the way premium cataract surgeries are performed, and we believe that ALLY addresses all limitations of current competitive technologies.” said Nick Cur..."
08/16/2022 8-K Quarterly results
08/09/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy